Bell EH, Zhang P, Shaw EG, et al. - Given that a adjuvant chemoradiotherapy was shown to offer a survival advantage over radiotherapy for patients with WHO low-grade glioma (LGG, grade II) for the first time in NRG Oncology/RTOG 9802, researchers performed this post hoc analysis to ascertain the prognostic as well as the predictive effect of the WHO-defined molecular subgroups and corresponding molecular changes within NRG Oncology/RTOG 9802. Following adjustment for clinical variables and treatment, progression-free survival was shown to be significantly predicted by WHO subgroup in multivariable analyses. This work represents the first to document the predictive worth of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. That the addition of procarbazine, lomustine (CCNU), and vincristine is beneficial for patients with IDH-mutant high-risk LGG irrespective of codeletion status is supported by the findings.